Leukaemia Cancer Leukaemia
Conditions
Interventions
ABCM for plateau induction with alpha Interferon (IFN) maintenance/a three-phase regimen of C-VAMP, high dose melphalan (with autologous bone marrow/peripheral blood stem cell support as appropriate)
Sponsors
Medical Research Council (MRC) (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. They have definite myelomatosis requiring chemotherapy and fulfilling at least two of the three following criteria: bone marrow aspirate and/or trephine showing the presence of a neoplastic plasma cell infiltrate and/or microplasmacytomas, a paraprotein present in blood and/or urine 2. They have definite lytic bone lesions 3. They are aged under 65 years 4. They are able to tolerate a daily fluid intake of not less than 3 litres 5. The physician is satisfied it would be appropriate to receive any of specified treatments
Exclusion criteria
Exclusion criteria: 1. Patients have equivocal myelomatosis (these should be registered but will not receive treatment - if disease progresses then they may be entered into the main trial) 2. They have previous malignancies except non-melanoma skin tumours or in situ carcinomas 3. Had previous treatment except minimal local radiotherapy to relieve bone pain 4. If have a life threatening disease unrelated to myelomastosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed